
The US has named India, China and Pakistan among 23 "major drug transit or major illicit drug producing countries" for fiscal year 2027. President Donald Trump welcomed Prime Minister Narendra Modi's efforts…
The US has named India, China and Pakistan among 23 "major drug transit or major illicit drug producing countries" for fiscal year 2027. President Donald Trump welcomed Prime Minister Narendra Modi's efforts against illicit opium poppy cultivation and said he looked forward to continued cooperation through the US-India Drug Policy Framework.

The White House clarified inclusion on the list does not mean a government is failing to combat drug trafficking, and may be due to geographic or economic factors. India was not among the four countries the US said "failed demonstrably" to meet counternarcotics obligations, a designation given to Afghanistan, Bolivia, Burma and Colombia.
Trump pressed China, calling it the world's largest producer of precursor chemicals for synthetic drugs, and urged Beijing to take more aggressive action. The list also includes Afghanistan, Mexico, Venezuela and 14 other nations. India was also on the previous year's list.
All three outlets reported the same White House determination neutrally, with no significant framing differences. Hindustan Times and India Today both led with Trump's praise for India, while Livemint foregrounded India's inclusion alongside China and Pakistan. The story's key fact is that the US explicitly separated India from the four countries it deemed failing on counternarcotics. The practical impact is limited: the designation is largely procedural and India remains on a list it was on last year. The US-India Drug Policy Framework continues.
Coverage: 3 sources, 3 neutral
Sources (3): hindustantimes.com (neutral report), livemint.com (neutral report), indiatoday.in (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry.
Updated: this story now draws on 3 sources.